Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Current Opinion in Oncology|March 19, 2016
Multifaceted and personalized therapy of advanced prostate cancerManish K Thakur, Ulka VaishampayanLung Cancer (Auckland, N.Z.)|March 16, 2017
Spotlight on necitumumab in the treatment of non-small-cell lung carcinomaManish K Thakur, Antoinette J WozniakSeminars in Respiratory and Critical Care Medicine|October 13, 2016
Predictive and Prognostic Biomarkers in Non-Small Cell Lung CancerManish K Thakur, Shirish M GadgeelJournal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 10, 2017
Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results (SEER) DataManish K Thakur, Julie J Ruterbusch, Ann G Schwartz, et al.Cell Chemical Biology|January 8, 2019
What Makes a Kinase Promiscuous for Inhibitors?Sonya M Hanson, George Georghiou, Manish K Thakur, et al.Clinical Genitourinary Cancer|March 15, 2018
Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate CancerManish K Thakur, Lance Heilbrun, Kimberlee Dobson, et al.World Journal of Gastroenterology|September 12, 2008
Anti-HBc screening in Indian blood donors: still an unresolved issueHari-Krishan Dhawan, Neelam Marwaha, Ratti-Ram Sharma, et al.Investigational New Drugs|November 20, 2015
A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) studyManish K Thakur, Lance K Heilbrun, Shijie Sheng, et al.Nature Chemical Biology|September 27, 2022
Discovery and molecular basis of subtype-selective cyclophilin inhibitorsAlexander A Peterson, Aziz M Rangwala, Manish K Thakur, et al.Nature Communications|November 14, 2022
Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistanceDhivya Sridaran, Surbhi Chouhan, Kiran Mahajan, et al.Pageof 2